GlycoNex
GlycoNex Inc. is a Taiwanese biotech company founded in 2001, specializing in glycan-targeted cancer therapy and antibody development. It has built a comprehensive technology platform, acquired crucial patents, and progressed in developing monoclonal antibody drugs and biosimilars. The company is actively engaged in clinical trials, patent applications, and international collaborations to advance cancer treatments and biosimilars, aiming to improve human health and welfare. Recently, GlycoNex has expanded its portfolio with the development of biosimilar drugs like SPD8, which has successfully entered licensing agreements for development and commercialization in specific markets, marking a significant milestone in its global expansion strategy. The company also continues to advance its innovative antibody-drug conjugates (ADCs) and biosimilars, with ongoing clinical trials and patent protections, demonstrating its commitment to innovative cancer therapies.
Industries
Nr. of Employees
medium (51-250)
GlycoNex
8F., No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221, Taiwan
Patents
Antibodies against extended type 1 chain antigens, derivatives thereof and use
US-8703129-B2
View DetailsAnti-extended type I glycosphingolipid antibody, derivatives thereof and use
US-8163497-B2
View Details
Antibodies against extended type 1 chain antigens, derivatives thereof and use
US-8703129-B2
View DetailsAnti-extended type I glycosphingolipid antibody, derivatives thereof and use
US-8163497-B2
View DetailsProducts
Clinical‑stage glycan‑targeting monoclonal antibody
A humanized monoclonal antibody targeting tumor‑associated glycan antigens with demonstrated preclinical tumor growth inhibition and completed Phase I assessment; protected by patents in multiple jurisdictions and progressed toward ADC development with CDMO manufacturing arrangements.
Antibody‑drug conjugate candidate based on glycan‑targeting antibody
Preclinical ADC program combining a glycan‑targeting antibody with cytotoxic payloads; preclinical evaluation completed and manufacturing agreements established with specialized CDMOs for clinical supply.
Denosumab biosimilar in late‑stage clinical development (out‑licensed)
A biosimilar to an anti‑RANKL monoclonal antibody advanced into Phase III clinical trials and subject to an out‑licensing agreement granting a third party development and commercialization rights in specified territories, with milestone and future royalty potential.
Clinical‑stage glycan‑targeting monoclonal antibody
A humanized monoclonal antibody targeting tumor‑associated glycan antigens with demonstrated preclinical tumor growth inhibition and completed Phase I assessment; protected by patents in multiple jurisdictions and progressed toward ADC development with CDMO manufacturing arrangements.
Antibody‑drug conjugate candidate based on glycan‑targeting antibody
Preclinical ADC program combining a glycan‑targeting antibody with cytotoxic payloads; preclinical evaluation completed and manufacturing agreements established with specialized CDMOs for clinical supply.
Denosumab biosimilar in late‑stage clinical development (out‑licensed)
A biosimilar to an anti‑RANKL monoclonal antibody advanced into Phase III clinical trials and subject to an out‑licensing agreement granting a third party development and commercialization rights in specified territories, with milestone and future royalty potential.
Services
Analytical characterization of glycans from biologics and biological samples using liquid chromatography, mass spectrometry and antibody‑based reagents to support therapeutic and biosimilar development.
Efficacy testing in tumor models and GLP‑style toxicology/exposure studies in rodents and non‑human primates to inform clinical starting doses and IND submissions.
Design and conduct support for first‑in‑human Phase I trials including dose escalation/expansion, multi‑center coordination and cross‑border regulatory alignment.
Business development services including confidentiality agreements, licensing negotiations, out‑licensing deal execution and coordination of milestone/royalty arrangements with commercial partners.
Sourcing, contracting and coordination with specialized CDMOs to produce GMP drug substance/drug product for antibody therapeutics and ADCs to support clinical supply.
Analytical characterization of glycans from biologics and biological samples using liquid chromatography, mass spectrometry and antibody‑based reagents to support therapeutic and biosimilar development.
Efficacy testing in tumor models and GLP‑style toxicology/exposure studies in rodents and non‑human primates to inform clinical starting doses and IND submissions.
Design and conduct support for first‑in‑human Phase I trials including dose escalation/expansion, multi‑center coordination and cross‑border regulatory alignment.
Business development services including confidentiality agreements, licensing negotiations, out‑licensing deal execution and coordination of milestone/royalty arrangements with commercial partners.
Sourcing, contracting and coordination with specialized CDMOs to produce GMP drug substance/drug product for antibody therapeutics and ADCs to support clinical supply.
Expertise Areas
- Glycan‑targeted antibody therapeutics
- Monoclonal antibody discovery and engineering
- Antibody‑drug conjugate (ADC) development
- Biosimilar development and late‑stage clinical programs
Key Technologies
- Glycan‑specific antibody libraries
- Liquid chromatography (LC) for glycan analysis
- Mass spectrometry (MS) for glycan profiling
- Next‑generation sequencing (NGS) for tumor profiling
News & Updates
GlycoNex announced that its anti-cancer drug GNX102 received US patent approval, marking a milestone in global patent strategy.
GlycoNex showcased its pipeline including GNX102, GlycoSH antibody library, and biosimilars at the BIO International Convention in San Diego.
GlycoNex reported progress in clinical trials and patent applications for GNX102 and biosimilars, emphasizing global market strategies.
GlycoNex announced the start of detailed mechanism and efficacy studies for GNX102 to optimize clinical trial design.
GlycoNex announced that GNX102 successfully completed Phase 1 clinical trial, demonstrating safety and initial efficacy, and plans for ADC development.
Research on Lock-Antibody technology combining glycan-specific antibodies with protease-activatable platform published, showing high tumor specificity and safety.
GlycoNex announced that its anti-cancer drug GNX102 received US patent approval, marking a milestone in global patent strategy.
GlycoNex showcased its pipeline including GNX102, GlycoSH antibody library, and biosimilars at the BIO International Convention in San Diego.
GlycoNex reported progress in clinical trials and patent applications for GNX102 and biosimilars, emphasizing global market strategies.
GlycoNex announced the start of detailed mechanism and efficacy studies for GNX102 to optimize clinical trial design.
GlycoNex announced that GNX102 successfully completed Phase 1 clinical trial, demonstrating safety and initial efficacy, and plans for ADC development.
Research on Lock-Antibody technology combining glycan-specific antibodies with protease-activatable platform published, showing high tumor specificity and safety.